Valneva SE (NASDAQ:VALN – Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 6,587 shares traded hands during mid-day trading, an increase of 40% from the previous session’s volume of 4,706 shares.The stock last traded at $8.80 and had previously closed at $9.02. Analysts Set New Price Targets VALN has been the topic […]
Valneva SE (NASDAQ:VALN – Get Free Report)’s share price gapped down before the market opened on Monday . The stock had previously closed at $8.88, but opened at $8.50. Valneva shares last traded at $8.50, with a volume of 923 shares. Analyst Ratings Changes Several research analysts have issued reports on VALN shares. HC Wainwright […]
Valneva SE (NASDAQ:VALN – Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $10.55, but opened at $10.22. Valneva shares last traded at $10.17, with a volume of 3,197 shares. Wall Street Analyst Weigh In A number of brokerages have issued reports on VALN. HC Wainwright […]
21st Austria weekly - Valneva Vienna Stock Exchange 29/12/2023 [pic1]Valneva: Valneva SE a specialty vaccine company today announced that the Company is modifying its financial guidance for 2023. Product sales remains unchanged as do anticipated R&D expenses. The €90 million to €110 of other income related proceeds from potential sale Company’s priority review voucher PRV which was previously expected before year-end now in early 2024.The previous included total revenues and between €220 €260 million. modified 2023 includes stated product revenue €130 €150 million on track achieve well expenses €60 €70 were recently reduced primarily driven by lower than costs closeout COVID-19 activities. Peter Bühler Chief Financial Officer
The EMA "has determined that all essential regulatory elements required for scientific assessment were included in the application," Valneva said in a statement. Accelerated assessment reduces the timeframe the EMA review to 150 days from 210 days, Valneva said.